Introduction {#s01}
============

The vertebrate inner ear is a complex structure comprised of the auditory (cochlear) and balance (vestibular) systems, which are responsible for perception of sound and gravitational/angular acceleration ([@bib19]), respectively. Arising from a simple epithelium, the otic placode, the inner ear undergoes extensive morphogenesis and differentiation, ultimately giving rise to many different cell types that are arranged to form an organ of exquisite complexity ([@bib15]; [@bib13]). Comprised of cells as diverse as mechanosensory hair cells, sensory neurons, and support cells, defects in inner ear development lead to hearing loss and balance disorders, which are among the most common of live birth defects ([@bib44]; [@bib49]; [@bib21]).

The otic placode begins as a thickening of the ectoderm adjacent to the developing hindbrain. As development proceeds, the placode invaginates to form the otic pit that subsequently develops into a cup that pinches off the ectoderm and closes dorsally to form the otic vesicle (otocyst). Invagination of placode cells to form the otocyst requires extensive cell shape changes, cell movements, and rearrangements that require remodeling of cell--matrix and cell--cell interactions among otic cells, as well as with the adjacent hindbrain ([@bib23]; [@bib10]; [@bib36]; [@bib50]). As development proceeds, the otic vesicle becomes regionalized, undergoes extensive proliferation, and finally differentiates into the vestibular and cochlear components of the inner ear ([@bib4]; [@bib37]). In the chick embryo, formation of a detectable otic placode is first apparent next to rhombomeres 5 and 6 of the hindbrain by Hamburger and Hamilton stage 10, by which time otic specification is complete. Invagination begins at stage 12, resulting in the formation of an otic cup that closes to form the internalized otic vesicle by stages 18--20 ([@bib2]; [@bib45]; [@bib4]; [@bib40]; [@bib41]).

Understanding the molecular mechanisms that regulate the spatiotemporal expression of genes involved in otic placode development is critical for elucidating both normal development and defects that may lead to hearing impairment. Numerous transcription factors, including *Pax2*, *Dlx3*, *Dlx5*, *Nkx5.1*, *SOHo1*, and *Sox10*, have been implicated in various aspects of ear development, primarily with respect to their roles in otic specification and subsequent differentiation ([@bib18]; [@bib3]; [@bib11]; [@bib5]; [@bib15]). For example, *Pax2* expression initiates within the early otic placode at stage 8 and plays an essential role in its specification ([@bib15]; [@bib25]), whereas *Sox10* is expressed later and is likely involved in differentiation events ([@bib14]; [@bib20]). In contrast to the role of transcriptional regulation during ear development, virtually nothing is known about the role of epigenetic regulators therein.

In this study, we report that lysine-specific demethylase 4B, KDM4B (also known as JmjD2B), is expressed in the developing otic placode, consistent with a possible role as an epigenetic modifier of inner ear development. The KDM4/JumonjiD2 family of histone lysine demethylases removes H3K9me3/me2 and H3K36me3/me2 methylation marks ([@bib17]; [@bib47]) and thus activates or represses expression of target genes, respectively. Despite their likely importance as epigenetic regulators, surprisingly little is known about the developmental roles of the KDM4 family or other epigenetic modifiers in vivo ([@bib46]). Here, we show that KDM4B is necessary for proper invagination of the otic placode, with its loss resulting in malformed placodes that fail to form vesicles of the proper size and shape. In vivo chromatin immunoprecipitation (ChIP) further demonstrates that the *Dlx3* gene, previously hypothesized to play a role in placode invagination ([@bib11]), is a direct target of KDM4B. These results reveal for the first time an epigenetic contribution to the control of inner ear invagination in vertebrate embryos via modulation of histone methylation.

Results {#s02}
=======

KDM4B is expressed during chick otic placode specification/invagination, and its loss of function results in abnormal maintenance of H3K9me3 marks {#s03}
--------------------------------------------------------------------------------------------------------------------------------------------------

As we previously detected *Kdm4b* expression by quantitative PCR (qPCR) in the early embryos at the time of otic placode formation ([@bib46]), we analyzed the spatial expression of *Kdm4b* by whole-mount in situ hybridization (ISH). We confirmed that *Kdm4b* is expressed in presumptive otic ectoderm by stage 9 (6 somite stage \[ss\]), persists through stage 9 (8ss), and by stage 12 (16ss) is confined to the border of the otocyst ([Fig. 1](#fig1){ref-type="fig"} and [Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp1}). We compared the expression of *Kdm4b* transcripts by whole-mount ISH from stages 11 and 13 with the early inner ear marker PAX2. At stage 11 ([Fig. 1 A](#fig1){ref-type="fig"}), *Kdm4b* expression overlaps with PAX2 ([Fig. 1 C](#fig1){ref-type="fig"}). However, by stage 13, *Kdm4b* expression shifts to the edges of the invaginating otocyst ([Fig. 1 B](#fig1){ref-type="fig"}), only minimally overlapping with a few PAX2-positive cells ([Fig. 1 D](#fig1){ref-type="fig"}). These observations indicate that *Kdm4b* is dynamically expressed during the invagination phases of otic development, raising the possibility that histone demethylation via KDM4B may occur in a stage- and site-specific manner.

![***Kdm4b* is expressed during otic placode specification/invagination.** (A and B) ISH of chick embryos at stages 11 (A) and 13 (B) with an antisense probe for *Kdm4b* transcripts. A' and B' are magnifications in the region of interest. A'' and B'' are transverse sections, as indicated by the dotted lines in A and B. (C and D) Immunostaining with the PAX2 antibody on transverse sections through *Kdm4b* in situ hybridized embryos reveal overlap of PAX2 and *Kdm4b* expression throughout the otic ectoderm at stage 11 (C) that diminishes by stage 13 (D), when *kdm4b* becomes restricted to the edges. Bars, 200 µm.](JCB_201503071_Fig1){#fig1}

Next, we assessed the distribution of the KDM4B substrate H3K9me3 by immunohistochemistry at similar stages of otic development. At stage 11, H3K9me3-positive cells were detected throughout the otic placode ([Fig. 2 A](#fig2){ref-type="fig"}); however, by stage 13, the mark was largely confined to cells along the edges of the invaginating otic vesicle ([Fig. 2 B](#fig2){ref-type="fig"}). These results reveal in vivo dynamic spatial distribution of both the H3K9me3 epigenetic mark and *Kdm4b* transcripts in the otic and invaginating placode.

![***Kdm4b* loss of function results in abnormal maintenance of H3K9me3 marks.** (A and B) H3K9me3 immunostaining in wild-type (WT) embryos at stages 11 (A) and 13 (B), showing the distribution of the epigenetic mark within the otic placode. At stage 11, H3K9me3 is relatively uniform, whereas by stage 13, staining is restricted to the rim of the otic ectoderm. (C--F) Electroporation of KDM4B-MO (F') followed by immunostaining for H3K9me3 at stage 13 (E and F) shows that the distribution of the epigenetic mark increases after KDM4B knockdown compared with the control side (C and D). Otic placode territories are indicated by dashed outlines. Bars, 20 µm.](JCB_201503071_Fig2){#fig2}

The correlation of the spatial localization of *Kdm4b* at stages 11 and 13 ([Fig. 1](#fig1){ref-type="fig"}) with changes in H3K9me3 distribution raised the intriguing possibility that KDM4B may be responsible for removal of the triple methylation mark during otic placode invagination. To test this, we performed KDM4B loss-of-function experiments by electroporating a fluorescein-tagged antisense morpholino (MO) into the right otic ectoderm of stage 8 embryos, leaving the left side as an internal control. Immunostaining revealed the persistence of the H3K9m3 epigenetic mark at stage 13 throughout the entire placode region on the KDM4B-MO--treated side ([Fig. 2, E and F](#fig2){ref-type="fig"}) compared with the control side, where the mark was restricted to the edges of the otocyst ([Fig. 2, C and D](#fig2){ref-type="fig"}). These results show that KDM4B is necessary for removal of the repressive H3K9me3 methylation mark in the developing ear.

KDM4B loss of function results in ear deformities and reduction in marker gene expression {#s04}
-----------------------------------------------------------------------------------------

The dynamic expression of *Kdm4b* and its substrate is consistent with the possibility that KDM4B plays an important role in regulating otic vesicle development. To further test this, we performed loss-of-function experiments at stage 8 as described in the previous section and examined embryos at stage 13 for the expression of the ear markers *Dlx3*, *SOHo1*, *Pax2*, and *Sox10* by ISH. Whole-mount and section analyses revealed that KDM4B-MO--electroporated otic vesicles were deformed in shape and exhibited a reduction in the expression domains of all inner ear markers examined when compared with the uninjected side of the same embryo ([Fig. 3, A--D](#fig3){ref-type="fig"}) or with control-MO--treated embryos ([Fig. 3, E--H](#fig3){ref-type="fig"}). Embryos were categorized according to the severity of the ear reduction phenotype as strong, mild, or none ([Fig. S2, A--C](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp2}). Some of the phenotypes observed were so severe that there was no sign of an otic vesicle, and *SOHo1* expression was completely absent (Fig. S2 A). For all of the genes analyzed, we observed a significant increase in the severity of the phenotypes compared with control-MO--treated embryos (Fig. S2 D). To further analyze the reduction of the otic domain, we quantified the expression of *Dlx3*,*Pax2*, *SOHo1*, and *Sox10* transcripts by qPCR from stage 13 otic vesicles that were electroporated with KDM4B-MO compared with uninjected vesicles. The results show a consistent reduction in the expression of *SOHo1* and *Dlx3* genes caused by the depletion of KDM4B, with less obvious changes for *Sox10* and *Pax2* ([Fig. 3 I](#fig3){ref-type="fig"}). It is interesting to note that on the dissected tissue used for this experiment, *SOHo1* and *Dlx3* are exclusively expressed in the otic placode cells, whereas *Sox10* and *Pax2* are also expressed in surrounding tissues such as neural crest and epibranchial placode cells, respectively. To demonstrate the specificity of the MO, we performed a Western blot analysis that confirmed a marked reduction of KDM4B protein after MO knockdown on the injected compared with uninjected sides of the same embryos ([Fig. 3 J](#fig3){ref-type="fig"}). In addition, we performed rescue experiments in which KDM4B-MO was coelectroporated with an expression vector containing a KDM4B coding sequence. The result showed a significant attenuation (P \< 0.01) in the severity of the phenotypes compared with KDM4B-MO plus an empty vector ([Fig. 3, K and L](#fig3){ref-type="fig"}; and Fig. S2 E). However, when a vector containing a catalytically dead mutant version of KDM4B (KDM4BΔ) was coelectroporated with the KDM4B-MO, there was no rescue, demonstrating that catalytic activity of the enzyme plays a critical role ([Fig. 3 M](#fig3){ref-type="fig"} and Fig. S2 E).

![**KDM4B loss of function results in ear deformities and reduction in marker gene expression.** (A--H) Electroporation of KDM4B-MO into the right side of the embryo (green staining in inset) causes a dramatic reduction in the otic placode domain as indicated by the expression of the otic placode markers *Soho1*, *Pax2*, *Sox10*, and *Dlx3* in embryos examined at stages 12/13 (A--D), compared with the left uninjected side and control-MO--treated embryos (E--H). Transverse sections (A'--D') reveal disorganization of the otic tissue. (I) RT-qPCR analyses show a consistent reduction in *Dlx3* and *SOHo1* expression, but moderate for *Sox10* and *Pax2*, on the KDM4B-MO--injected side (IS) compared with the uninjected side (UIS). Vertical bars represent the ΔΔCt ratio between the injected and uninjected side from the same pool of embryos. Vertical error bars on data points represent the standard error of mean obtained from three independent samples, including eight otic vesicles on each. Horizontal dotted line indicates the threshold ΔΔCt ratio (injected side/uninjected side = 1). (J) Western blot analysis, performed from 16 isolated otic vesicles, reveals a 36% reduction of KDM4B protein expression on the KDM4B-MO--injected side compared with the ­uninjected side. (K--M) Electroporation of KDM4B-MO (green fluorescence in inset), together with a vector containing the coding region of KDM4B, rescues the depletion of *SOHo1* as assayed by ISH and the otic placode invagination (L). In contrast, coelectroporation of KDM4B-MO plus an empty vector (K) or catalytically dead mutant of *Kdm4b* (KDM4BΔ; M) failed to rescue the loss-of-function phenotype (see [Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp3} for phenotypes quantitation). Bars: (A--H and K--M) 200 µm; (A'--D') 20 µm.](JCB_201503071_Fig3){#fig3}

Collectively, these results demonstrate that KDM4B demethylation activity is required for the correct expression of several ears markers, and its perturbation causes profound defects in inner ear formation, highlighting the importance of epigenetic regulation during this process.

Depletion of KDM4B protein transiently increases cell proliferation and cell death {#s05}
----------------------------------------------------------------------------------

The striking change in otic vesicle morphology and ear marker gene expression after a reduction of KDM4B levels suggests that proper levels of this demethylase are required for the cellular mechanisms underlying inner ear growth and morphogenesis. To assess whether the otic phenotype of KDM4B-MO--treated embryos might result from a defect in cell proliferation, we performed BrdU incorporation assays to assess S-phase occupancy, as well as cell counts using Hoechst staining and phosphohistone H3 (pH3) immunostaining to analyze mitotic activity at different stages ([Fig. 4](#fig4){ref-type="fig"}). At stage 11, BrdU incorporation assays revealed a slight but significant increase in the number of S-phase cells (P = 0.0488), with control otic vesicle sections containing a mean of 42 ± 4.76 positive cells and KDM4B-MO--injected vesicles containing 55 ± 2.27 BrdU-positive cells ([Fig. 4, A, D, and G](#fig4){ref-type="fig"}). Total cell counts revealed a corresponding increase in the mean number of cells within the otic placode domain at stage 12, with control otic sections containing a mean of 97.4 ± 1.63 cells, whereas KDM4B-MO--injected vesicles had a mean of 123.8 ± 9.02 cells (P = 0.0205; [Fig. 4, B, E, and H](#fig4){ref-type="fig"}). In addition, mitotic activity was examined using pH3 immunohistochemistry at stages 11--13 ([Fig. 4 I](#fig4){ref-type="fig"}). There was no significant increase (P = 0.1059) in the number of pH3-positive cells on the MO-injected side at stage 11, by which time the otic placode is already specified. By stage 12, however, a significant increase in the number of pH3-positive cells was observed (P = 0.0322), with control otic sections containing a mean of 29.4 ± 3.14 dividing cells and KDM4B-MO otic sections containing a mean of 39.6 ± 2.38 dividing cells ([Fig. 4 I](#fig4){ref-type="fig"}). Interestingly, the total number of pH3-positive cells significantly declined at stage 13 (P = 0.0286), by which time the otic pit has formed, with KDM4B-MO vesicles exhibiting 6.6 ± 0.75, whereas control otic vesicles contained a mean of 11.6 ± 1.72. To determine if this reduction in cell proliferation is accompanied by cell death, we performed Caspase3 immunostaining in sections through the ear of KDM4B-MO--treated embryos ([Fig. 4, C, F, and J](#fig4){ref-type="fig"}). Accordingly, by stages 12 and 13, we observed a significant increase in cell death upon depletion of KDM4B (P = 0.0491).

![**Depletion of KDM4B protein transiently increases cell proliferation and cell death.** BrdU assays (A, D, and G), cell counts (B, E, and H), and pH3 immunostaining (I) performed on KDM4B-MO--treated embryos reveal a transient increase in cell proliferation at stage 12. At stages 12/13, there was an increase in cell death observed with Caspase3 immunostaining (C, F, and J) on the KDM4B-MO--treated side compared with the control side. Dashed lines outline the otic placodes in A--F. Error bars indicate ±SEM. \*\*, P \< 0.05 with Student's *t* test. Bars, 40 µm.](JCB_201503071_Fig4){#fig4}

Taken together with the morphological changes noted in Figs. [2](#fig2){ref-type="fig"}and[3](#fig3){ref-type="fig"}, the results suggest that loss of KDM4B function causes a striking change in otic morphology accompanied by a transient increase in the number of placode cells in S phase and undergoing mitosis when the otic cup normally undergoes invagination, followed by cell death.

Knockdown of KDM4B affects the polarization of adhesion molecules on otic placode cells {#s06}
---------------------------------------------------------------------------------------

During otic placode invagination, epithelial cells undergo shape changes mediated intracellularly by cytoskeletal changes and extracellularly by cell adhesion molecules. This leads to progressive invagination, ending with closure to form the otocyst ([@bib23]; [@bib36]). Morphometric studies have shown that otic invagination is biphasic. Phase one involves a basal expansion to make the initial depression, and phase two comprises an apical constriction that guides the gradual hollowing of the otic vesicle ([@bib2]; [@bib40]; [@bib41]). During apical constriction phases, epithelial cells express cadherin adhesion molecules, well known for their involvement in cell--cell adhesion events during embryonic development ([@bib35]).

The profound changes in epithelial cell shape within the otic placode after KDM4B knockdown raised the intriguing possibility that this phenotype might be accompanied by changes in adhesive interactions between the cells. To examine this possibility, we analyzed the effects of KDM4B knockdown on the localization of E-cadherin (E-cad), the cadherin most prominently expressed throughout the embryonic ectoderm ([Fig. 5](#fig5){ref-type="fig"}). At stage 12, E-cad was enriched uniformly along cell membranes in control otic vesicles ([Fig. 5 A](#fig5){ref-type="fig"}), clearly revealing cell shapes that were oriented along the apical--basal axis. In stark contrast, KDM4B-MO--treated otic cells exhibited a nonuniform and disorganized distribution of E-cad along their membranes ([Fig. 5 B](#fig5){ref-type="fig"}), revealing perturbed cell shapes and suggesting that cadherin-mediated adhesion was disrupted. To further investigate this, we analyzed the distribution of β-catenin, a component of the cadherin-mediated adhesion complex. At stage 12, β-catenin was enriched along the apical surface of control otic vesicles, during which time the otic placode was invaginating ([Fig. 5 C](#fig5){ref-type="fig"}). In contrast, β-catenin localization in KDM4B-MO--treated otic tissue was not apically enriched, but instead, it was disorganized ([Fig. 5 D](#fig5){ref-type="fig"}), in agreement with observations of E-cad distribution.

![**Depletion of KDM4B affects the polarization of adhesion molecules on otic placode cells.** Subcellular localization of E-cad, β-catenin, and phalloidin staining by stages 12 (A--D) and 13 (E and F) at the onset of otic invagination on the control- (A, C, and E) and KDM4B-MO--treated sides (B, D, and F). The results show mislocalization of E-cad and β-catenin at stage 12 as well as disorganization of actin filaments, as revealed by phalloidin staining, on the KDM4B-MO--injected compared with the uninjected side in stage 13. Bars: (A--F) 50 µm; (A'--D') 20 µm.](JCB_201503071_Fig5){#fig5}

We next assessed E-cad distribution and apical constriction at stage 13. Although on the control side the distribution of E-cad was polarized, localized to the apical side of invaginating placode cells ([Fig. 5 E](#fig5){ref-type="fig"}), E-cad was not apically enriched on the KDM4B-MO--electroporated side. Instead, it appeared evenly distributed along the cell membrane of all placodal cells, which appeared to have lost polarity ([Fig. 5 F](#fig5){ref-type="fig"}). Indeed, the morphology of the otic placode was disorganized and invagination failed. During normal otic placode development, actin filaments exhibit an apical-to-basal polarity and upon invagination are rearranged and become enriched apically ([@bib40]). After KDM4B loss of function, however, phalloidin staining revealed a loss of actin filament polarity ([Fig. 5 F](#fig5){ref-type="fig"}) compared with the control side ([Fig. 5 E](#fig5){ref-type="fig"}). To quantitate the change of cell polarity during the invagination process, we measured the nuclear angles, toward a horizontal median, along the mediolateral axis in transverse sections stained with Hoechst. This analysis revealed a lack of a proper nuclear orientation and columnar morphology on the KDM4B-MO--treated side compared with the untreated side ([Fig. S4](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp4}).

Thus, actin filament polarity as well as E-cad and β-catenin distribution appear mislocalized after reduction of KDM4B, accompanied by misalignment of otic cells. Collectively, the results suggest that the failure of proper otic invagination after exposure to KDM4B-MO may reflect impairment of cell--cell interactions and cell polarization.

KDM4B binds to the Dlx3 regulatory region and is required for demethylation of H3K9me3 at the Dlx3 promoter {#s07}
-----------------------------------------------------------------------------------------------------------

To test whether KDM4B may directly regulate otic marker gene expression by histone demethylation, which in turn impacts otic invagination, we examined whether the histone demethylase directly interacts with regulatory regions of key otic transcription factors. To this end, we performed in vivo ChIP-qPCR on ∼30--40 dissected otic placodes from embryos at stage 11 using an anti-KDM4B antibody. We tested the occupancy of the KDM4B protein on regulatory regions of *SOHo1*, *Pax2*, and *Dlx3* genes ([Fig. 6](#fig6){ref-type="fig"}). Although no binding was observed to the known chromatic regions of *SOHo1* and *Pax2* ([Fig. 6, A and B](#fig6){ref-type="fig"}), we observed consistent binding to the first intron (1 kbp from the transcription start site \[TSS\]), but not to the promoter of the *Dlx3* gene at stage 11 ([Fig. 6 C](#fig6){ref-type="fig"}). Interestingly, this strong binding did not persist at stage 13 ([Fig. 6 C](#fig6){ref-type="fig"}), suggesting dynamic and transient regulation mediated by KDM4B during inner ear development.

![**Endogenous KDM4B binds to a regulatory region of Dlx3 locus during inner ear invagination.** (A--C) In vivo ChIP-qPCR assays were used to assess KDM4B binding to genes implicated in ear development such as *Soho1* (A), *Pax2* (B), and *Dlx3* (C). The vertical axes represent fold enrichment (specific ChIP/IgG enriched), and the numbers on the horizontal axes represent distances in kilobase pairs with respect to the TSS on the analyzed genes. Error bars show standard deviation. Schematic diagrams at the top show primer locations for each analyzed gene. One representative sample out of three independent experiments is depicted. The results show that KDM4B strongly associates with the *Dlx3* gene at the first intron (C), but not to *SOHo1* (A) or *Pax2* (B) at stage 11. This association was greatly diminished at stage 13 (C). (D) The results show high occupancy of H3K9me3 at −0.5 kb from the TSS of *Dlx3* at stage 11, though the repressive mark is clearly reduced by stage 13. (E) ChIP assays were performed on ∼20--30 stage 11 otic placodes from KDM4B-MO-- and control-MO--treated embryos. The results show a lack of KDM4B binding to the *Dlx3* locus on KDM4B-MO-- compared with control-MO--treated embryos. (F) H3K9me3 occupancy was greatly increased when knocking down KDM4B on the promoter region of *Dlx3*.](JCB_201503071_Fig6){#fig6}

We next assayed for H3K9me3 occupancy and observed pronounced enrichment of this epigenetic mark in the promoter region (−0.5 kbp from the TSS) of *Dlx3* at stage 11, also greatly diminished by stage 13 ([Fig. 6 D](#fig6){ref-type="fig"}). To demonstrate specificity, we repeated the ChIP with both anti-KDM4B and anti-H3K9me3 after KDM4B-MO knockdown. As predicted, the KDM4B occupancy on the *Dlx3* locus at stage 11 was greatly reduced after treatment with KDM4B-MO-- compared with control-MO--treated embryos ([Fig. 6 E](#fig6){ref-type="fig"}). Reciprocally, H3K9me3 occupancy on the *Dlx3* promoter clearly increased in KDM4B-MO--treated embryos, consistent with removal of demethylase activity. Collectively, these results demonstrate that KDM4B is recruited in proximity to the first intron of *Dlx3*, and its activity is responsible for demethylation of the H3K9me3 mark at the promoter of the *Dlx3* gene.

DLX3 is sufficient to rescue invagination defects after KDM4B knockdown {#s08}
-----------------------------------------------------------------------

The ChIP data suggest that KDM4B may affect otic invagination via regulation of *Dlx3* expression. To test this hypothesis, we next asked whether adding back DLX3 would rescue the effects of KDM4B loss. To this end, we coelectroporated KDM4B-MO together with an expression construct containing the *Dlx3* coding sequence into otic ectoderm at stage 8. Embryos were sorted for severity of phenotypes and immunostained for E-cad and phalloidin at stage 12/13 to assess the invagination phenotype. Remarkably, *Dlx3* expression was sufficient to rescue the severity of the phenotypes compared with KDM4B-MO plus empty vector ([Fig. 7](#fig7){ref-type="fig"} and [Fig. S5](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp5}). Phenotype quantitation showed that 80% of the analyzed embryos exhibited no otic invagination defects and displayed rescued otic vesicle size (Fig. S5, B and D), whereas 36% and 47% of embryos electroporated with KDM4B-MO plus empty vector exhibited strong and mild invagination phenotypes, respectively (Fig. S5, A and D). Immunohistochemistry revealed that E-cad distribution, actin polarity, and invagination ([Fig. 7, A--I](#fig7){ref-type="fig"}), as well as cell death (Fig. S5, E--G and K), were strikingly rescued after coelectroporation of KDM4B-MO with the *Dlx3* expression construct. In contrast, coelectroporation of KDM4B-MO plus an expression vector containing the *Dlx5* gene, another *Dlx* factor that is expressed during otic placode development, was not sufficient to rescue invagination defects (Fig. S5, C, D, and H--J). Collectively, these data show that KDM4B histone demethylase epigenetically influences otic placode invagination via modulating *Dlx3* gene expression.

![**Coelectroporation of KDM4B-MO with pCIG-Dlx3 was sufficient to rescue otic invagination.** Using immunohistochemistry, the control side (A--C) shows normal invagination as visualized by E-cad and phalloidin staining, but disrupted invagination on the KDM4B-MO--treated side (D--F). Coexpression of *Dlx3* (G--I) with KDM4B-MO was sufficient to rescue otic invagination, leading to a proper arrangement of actin filaments and correct localization of E-cad. Bars, 50 µm.](JCB_201503071_Fig7){#fig7}

Knockdown of Dlx3 causes similar phenotypes to KDM4B loss {#s09}
---------------------------------------------------------

As *Dlx3* expression was sufficient to rescue otic defects after knockdown of KDM4B, we postulated that DLX3 plays a key functional role during otic placode invagination. To test this hypothesis, we performed DLX3 loss-of-function experiments by electroporating a fluorescein-tagged antisense MO into the otic ectoderm at stage 8. At stage 12, DLX3 loss resulted in a failure in otic placode invagination ([Fig. 8 B](#fig8){ref-type="fig"}) when compared with the control side ([Fig. 8 A](#fig8){ref-type="fig"}). Apical accumulation of actin, as viewed by phalloidin, was also compromised compared with the control ([Fig. 8](#fig8){ref-type="fig"}, A′ and B′), indicating that the cellular rearrangements necessary for invagination failed to occur in a timely manner. These data show that *Dlx3* is one of the key genes required for proper otic placode morphogenesis.

![**Knockdown of Dlx3 results in failure of otic invagination.** The control side (A) shows normal invagination as seen by apical accumulation of actin filaments viewed by phalloidin staining. The electroporation of DLX3-MO compromise otic invagination (B), indicated by irregular rearrangement of actin filaments. (A' and B') Inset views indicate the lack of apical accumulation of actin filaments on the injected side. Bars: (A and B) 60 µm; (A' and B') 20 µm.](JCB_201503071_Fig8){#fig8}

Discussion {#s10}
==========

After its induction, the otic placode undergoes morphogenesis that transforms it from a flat ectodermal disk to a hollow internalized spherical vesicle. Experiments using otic placode explants have provided evidence that the invagination process occurs as a consequence of extrinsic signals that trigger a specific transcriptional program ([@bib40]). In addition, epigenetic modifications are gaining recognition as key regulators in the fine-tuning of gene expression and cell differentiation. In this study, we show that in addition to external signaling events, intrinsic epigenetic programs are necessary for proper otic morphogenesis. Our results demonstrate that the histone demethylase KDM4B is critical for otic invagination, with its loss causing abnormal ear morphogenesis. Moreover, we show that KDM4B functions by directly controlling expression of the *Dlx3* gene, in a spatiotemporally regulated manner, through H3K9me3 removal. These data reveal for the first time an epigenetic contribution to the control of inner ear invagination in vertebrate embryos via modulation of histone methylation.

Our finding that *Dlx3* is a direct target of KDM4B is consistent with the similar spatiotemporal expression patterns of *Kdm4b* (present study) and *Dlx3* ([@bib11]) transcripts during inner ear development. Like *Kdm4b*, *Dlx3* is highly expressed throughout the entire chick otic placode at stage 11, and its expression becomes restricted to the rim of the otic pit as invagination proceeds ([@bib11]). Our results show that KDM4B abundantly occupies the first intron of *Dlx3*, from which it exercises its demethylase activity on the H3K9me3 mark located at the promoter region of the gene. We speculate that the first intron of *Dlx3* may act as a KDM4B-recruiting element, thus allowing H3K9me3 removal and gene activation. Related to this, some studies have suggested that first introns may play a vital role in transcriptional regulation of genes ([@bib34]; [@bib31]). As a general trend, first introns are longer, highly conserved, and enriched in CpG dinucleotides compared with other introns ([@bib34]; [@bib28]; [@bib9]; [@bib38]), suggesting that they may contain regulatory elements. The methylation of CpG dinucleotide is also known to be involved in transcriptional regulation of genes by modifying chromatin structure and/or altering binding sites of transcription factors ([@bib42]; [@bib12]). *Dlx3* is no exception, as its first intron is embedded within a large CpG island, suggesting that this may play a critical role in recruitment of transcription factors necessary for its regulation. Interestingly, [@bib38] have shown that first introns are enriched in active transcriptional chromatin marks such as H3K4me3/me1. Related to this, there is evidence that double Tudor domains, present in KDM4 proteins, may recognize the H3K4me3 marks necessary for their recruitment to target chromatin regions ([@bib43]; [@bib30]).

Interestingly, *Dlx3* has been suggested to play a role in the regulation of extracellular matrix and adhesion molecules during the otic invagination process ([@bib23]; [@bib36]; [@bib50]). Consistent with this, injection of function-blocking antibodies to perturb the extracellular matrix prevents association of the otic primordium with the hindbrain and inhibits subsequent invagination ([@bib36]; [@bib50]). Oriented actin filaments and adhesion molecules, like E-cad and adherent junction proteins, have been shown to play an essential role in collective migration processes, including otic placode invagination ([@bib8]; [@bib48]; [@bib41]). Otic invagination occurs in a biphasic manner, initiating with basal expansion to generate the initial depression followed by apical constriction to drive the deepening of the otocyst ([@bib41]). During the first phase, extrinsic FGF signaling coordinates the depletion of basal actin filaments producing basal expansion of otic placode cells ([@bib40]). The second phase, which is regulated in a RhoA--Rho-associated protein kinase--dependent manner, results in myosin II activation necessary to direct the contraction of the apical actin networks that results in apical constriction ([@bib41]). These observed cytoskeletal changes necessary for proper otic placode invagination are similar to those perturbed by a KDM4B loss of function. In the present study, we noted a clear mislocalization of actin filaments and E-cad molecules, along with improper ear invagination.

The morphological changes observed after KDM4B loss correlated with a transient increase in cell proliferation at stages 11/12, which is the transitional stage during which the ectodermal invagination process initiates and gradually leads to the internalization of the developing ear. Then, at stage 13, we noted a cessation in cell proliferation and a significant increase in cell death. Collectively, we propose that after a loss of KDM4B, otic placode cells are unable to exit the cell cycle, and that this lack of early differentiation/invagination leads to apoptosis. Cell death normally occurs concomitant with invagination movements and proliferative activity in the otic epithelium ([@bib39]). Based on this, we hypothesize that alteration in the proliferation/death balance may also contribute to defects in otic morphological development, mainly by affecting the cell--cell interactions necessary for correct tissue folding.

The present data support an important role for *Dlx3* in otic invagination. Our loss-of-function experiments show that a DLX3 loss results in failure in otic invagination and striking morphological changes, including irregular accumulation of actin filaments. These observations are consistent with previous work in zebrafish showing that MO-mediated reduction of Dlx3b (Dlx3 homologous) delays specification of the otic placode and impairs complete maturation of the otic vesicle, resulting in formation of a smaller vesicle ([@bib32]; [@bib26]). Although the mechanistic link between *Dlx* genes and ear morphogenesis has yet to be elucidated, clues to its function may be gleaned from other systems. For example, during interneuron migration, *Dlx* genes are known to repress PAK3 (member of the p21-activated serine/threonine kinases family) that is required for cytoskeletal rearrangements ([@bib16]). PAK kinases are major downstream effectors of the Rho GTPases Rac1 and Cdc42 ([@bib7]; [@bib27]). In turn, Rho GTPases are thought to act as integrators of intrinsic and extrinsic signals to orchestrate cytoskeletal changes that influence cell motility ([@bib33]; [@bib24]) and apical constriction ([@bib35]). Accordingly, in the developing otic placode, we speculate that intrinsic epigenetic regulation of the *Dlx3* gene may affect the expression of analogous targets that in turn may control cytoskeletal rearrangements during ear development.

In summary, we provide strong evidence that early epigenetic influences are critical for regulating expression of transcription factors, most notably *Dlx3*, in the developing ear. Perturbation of this epigenetic fine-tuning leads to major downstream defects in ear formation. These results highlight the importance of and close connection between transcriptional and epigenetic regulatory programs during development in general and of the forming ear in particular.

Materials and methods {#s11}
=====================

Embryos {#s12}
-------

Fertilized chicken eggs were obtained from local commercial sources and incubated at 38°C to the desired stages according to the criteria of Hamburger and Hamilton.

Electroporation, MOs, and rescue experiments {#s13}
--------------------------------------------

An antisense MO oligomer to KDM4B was designed against a sequence near the ATG codon (5′-GTTTTCAGACCCCATATTTCCAGGA-3′) and against DLX3 near the ATG codon (5′-TCTTGTCGAAGGAGCCGCTCATCGC-3′). As a control, we used the standard control-MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′; Gene Tools, LLC). Injections of fluorescein-tagged MO (1--2-mM plus 0.3 µg/µl of plasmid DNA) and vectors, on the right side of the embryos, were performed by air pressure using a glass micropipette targeted to the presumptive otic placode region at stage 8, located lateral to somites 1 and 2. Electroporation was performed with five pulses of 8 V in intervals (30 ms on and 100 ms off). For rescue experiments, the construct included the coding region of KDM4B, the catalytically dead mutant (KDM4BΔ), *Dlx3*, or *Dlx5* in a pCI-IRES-H2BGFP vector. The pCIG-Dlx3 and pCIG-Dlx5 constructs were provided by M. Barembaum (Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA). For each embryo, 1-mM MO and 1 µg/µl DNA was used for KDM4B rescue and 1-mM MO and 1.5 µg/µl DNA for *Dlx3* and *Dlx5* rescue. KDM4BΔ was obtained by fusion PCR ([Table S1](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp6}) mutating specific amino acids (H189A, F186A, and E191Q), described to be necessary for the demethylation activity of KDM4B ([@bib22]; [@bib6]; [@bib29]), and then cloned into pCIG-IRES-H2B-RFP vector. We have confirmed that both vectors, containing KDM4B and KDM4BΔ, exhibit strong protein expression, as they were immunodetected in the nucleus of electroporated cells by using an anti-KDM4B antibody (rabbit anti-KDM4B; Novus Biologicals). Moreover, we have also demonstrated that KDM4B, but not KDM4BΔ, overexpression was able to erase the H3K9me3 modification on electroporated cells ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201503071/DC1){#supp7}).

After electroporation, eggs were sealed with tape and incubated to reach the desired stages. Embryos were removed from eggs, placed in PBS, and viewed and photographed as whole mounts using a fluorescence stereomicroscope to assay electroporation efficiency within the otic domain.

ISH {#s14}
---

Whole-mount ISH was performed as previously described ([@bib1]). Embryos were fixed overnight in 4% PFA at 4°C, washed in PBSw-DEPC (PBS-diethylpyrocarbonate containing 0.1% Tween), and dehydrated in MeOH/PBSw-DEPC series at RT before being stored at −20°C in 100% MeOH. After being rehydrated step-wise with decreasing concentrations of MeOH/ PBSw-DEPC Tween 0.1% and then washed three times with PBSw-DEPC, embryos were permeabilized using 10 µg/µl proteinase K at RT. Embryos were then hybridized at 70°C overnight with the desired digoxigenin (DIG)-labeled RNA probe. DIG-labeled RNA probes were synthesized from pCI plasmids containing the following cDNAs: *Kdm4b*, *Dlx3*, *Pax2*, *SOHo1*, and *Sox10*. Hybridized probes were detected using an alkaline phosphatase--conjugated anti-DIG antibody (1:2,000; Roche) in the presence of nitroblue tetrazolium/5-bromo-4-chloro-3-indolyphosphate substrates (Roche). Whole-mount pictures were taken at RT using AxioVision software (Carl Zeiss) with a microscope (Stemi SVII; Carl Zeiss), or with the software Image-Pro Plus 5.1 Biological (Media Cybernetics) with a camera (Evolution VF; Media Cybernetics) in a microscope (SMZ800; Nikon). After ISH, some embryos were fixed in 4% PFA in PBS, washed, embedded in gelatin, and cryostat sectioned at a thickness of 14--16 µm. They were photographed using the AxioVision software with a microscope (Axioskop 2 Plus; Carl Zeiss) and processed using Photoshop (CS3; Adobe).

Western blot {#s15}
------------

Otic vesicles were dissected from 16 unilaterally electroporated embryos with KDM4B-MO and snap frozen in liquid nitrogen and stored at −80°C. Afterward, the injected and uninjected pool of otic vesicles were lysed by homogenization using a plunger and 150 µl of protein extraction buffer (50-mM Tris-HCl, pH 7.5, 100-mM NaCl, and 5-mM EDTA) supplemented with protease inhibitor (Complete Protease Inhibitor; Roche) and 1% of NP-40. Subsequently, they were centrifuged for 5 min at 1,000 *g* at 4°C, and the supernatant containing the proteins was collected. Proteins were quantified by Bradford, and an equal amount was run into an SDS-PAGE and transferred to a membrane for blotting. Rabbit anti-KDM4B (Novus Biologicals) was diluted 1:1,000 to test the reduction in KDM4B protein, and a mouse antitubulin (Sigma-Aldrich) was diluted 1:2,000 as a loading control. Both primary antibodies were incubated overnight at 4°C. Finally, secondary conjugated goat anti--mouse HRP or anti--rabbit HRP was diluted 1:10,000 and incubated for 45 min at RT for posterior developing by using ECL plus reagents according to the manufacturer's instructions (GE Healthcare).

Immunohistochemistry {#s16}
--------------------

Fixed embryos were washed in 1× TBST (500-mM Tris-HCl, pH 7.4, 1.5-M NaCl, 10-mM CaCl~2~, and 0.5% Triton X-100) and subsequently blocked in 10% donkey serum in 1× TBST for 3--5 h at RT. Embryos were then incubated in either mouse anti--E-cad (1:1,000; 610181; BD), mouse anti--β-catenin (1:1,000; 6301; Abcam), rabbit anti-H3K9me3 (1:500; 8898; Abcam), rabbit anti-FITC (1:500; 71--1900; Invitrogen), goat anti-FITC (1:500; NB600-493; Novus Biologicals), or rabbit anti-Caspase3 (1:500; AF835; R&D Systems) overnight at 4°C. The secondary antibodies used were goat or donkey anti--mouse, donkey anti--goat, and anti--rabbit Alexa Fluor 350, 488, 594, and 647 (1:1,000; Molecular Probes), which were incubated for 45 min to 3 h at RT. After washes, embryos were briefly postfixed for 10 min at RT in 4% PFA, washed in 1× PBS, incubated in 15% sucrose/1× PBS for 1 h, and then embedded in 7.5% gelatin and 15% sucrose for cryosectioning. Sections of embryos were then incubated in 1:100 phalloidin 568 and/or Hoechst 3358 (1:2,000). Sections were then imaged on one of the following microscopes: Axioskop 2 Plus with AxioVision software; Zen software (Carl Zeiss) and a photon confocal microscope (LSM 710 2; Carl Zeiss) using a plan-apochromat/.95 korr 40× oil objective; an Image.M2 Apoptome.2 microscope (Carl Zeiss) using a plan-apochromat/.95 korr 40× oil objective; or the NIS-Elements AR4.00 software (Nikon) on a microscope (Eclipse E600; Nikon) using plan 10× 0.25 and plan 40× 0.65 objectives.

qPCR {#s17}
----

Three different batches of embryos were electroporated with KDM4B-MO unilaterally at stage 8 and incubated to stage 13. Otic placodes from the injected and the uninjected side were dissected separately. Total RNA was extracted using an RNAqueous-Micro isolation kit (Ambion) according to the manufacturer's instruction. After DNaseI-amplification grade (Invitrogen) treatment, 1 µg of total RNA was used for cDNA synthesis using SuperScriptII (Invitrogen) and random hexamers (Roche). qPCR was performed using a 96-well plate in MX3005P equipment (Agilent Technologies). Each reaction was performed using Fast Start Syber green (Roche) in a 15-µl volume. All the used primers (Table S1) were tested to have amplification efficiency ranging from 95 to 100%. The subsequent quantification method was done using the ΔΔCt method (threshold cycle). For a reference gene, we used a qPCR primer designed for the GAPDH gene. Gene expression levels are represented relative to GAPDH expression.

Proliferation assays {#s18}
--------------------

BrdU powder (Sigma-Aldrich) was dissolved (10 mM) in Ringer's solution and applied directly under the vitelline membrane via a glass needle adjacent to the KDM4B-MO--electroporated embryos at stage 11. Embryos were incubated at 38°C for 45 min and then fixed in 4% PFA for 25 min at RT for cryosectioning. Cryosections were briefly rehydrated with 1× PBS, incubated with 2-N HCl for 10 min at 37°C, and then immediately washed in PBS with Tween, blocked at RT, and incubated at 4°C overnight in mouse anti-BrdU (1:250; B8434; Sigma-Aldrich). For mitotic counts, sections of embryos treated with KDM4B-MO were incubated with an antibody against pH3 (1:500; EMD Millipore) and then detected using the secondary Alexa Fluor 568 goat anti--rabbit (1:1,000). Nuclei were detected by incubating sections in Hoechst 3358 with the secondary. All cell counts were performed within the otic ectoderm of KDM4B-MO--injected and --uninjected sides, and statistical significance was determined using Student's *t* test (Prism; GraphPad Software).

ChIP {#s19}
----

Approximately 20--40 otic placodes/otic pits were dissected from stage 11 and stage 13 embryos. The tissue was homogenized in nuclei extraction buffer (0.25% NP-40, 0.25% Triton X-100, 10-mM Tris-HCl, pH 7.5, 3-mM CaCl~2~, 0.25-M sucrose, 1-mM DTT, 0.2-mM PMSF, and EDTA-free protease inhibitor \[Roche\]). Cells were cross-linked with 1% formaldehyde for 10 min at RT, and the formaldehyde was then inactivated by the addition of 125-mM glycine for 5 min. Cross-linked cells were centrifuged, and the pellet was washed three times in cold PBS containing a protease inhibitor. The final pellet was snap frozen in liquid nitrogen and stored at --80°C until use. Cells were resuspended in nuclei extraction buffer and rehomogenized until the nuclei went to the solution. After the centrifugation, the pellet was resuspended in SDS-lysis buffer (1% SDS, 50-mM Tris-HCl, pH 8.0, 10-mM EDTA, and EDTA-free protease inhibitor), and 2 vol of ChIP dilution buffer (0.01% SDS, 1.2-mM EDTA, 16.7-mM Tris-HCl, pH 8.0, 167-mM NaCl, 1-mM DTT, 0.2-mM PMSF, and stock of Complete EDTA-free protease inhibitor) was added. Chromatin was sheared to 300--800-bp fragments using a sonicator (amp: 30%; cycle: 30 s on and 30 s off) for 15 min and centrifuged, and the supernatant was split in three tubes for input sample, mock control (rabbit anti-IgG; Abcam), and target antibodies of rabbit anti-KDM4B (Novus Biologicals) or rabbit anti-H3K9me3 (Abcam), all bound to protein A magnetic beads (Invitrogen). IgG and target antibodies (10 µg) were incubated overnight at 4°C, and after extensive washes with radioimmunoprecipitation assay buffer (50-mM Hepes-KOH, pH 8, 500-mM LiCl, 1-mM EDTA, 1% NP-40, 0.7% Na-deoxycholate, 1-mM DTT, 0.2-mM PMSF, and a stock of complete protease inhibitor), the complexes were resuspended in an elution buffer (50-mM Tris-HCl, pH 8.0, 10-mM EDTA, and 1% SDS). The magnetic beads were eluted by incubating at 65°C for 15 min and vortexing every 2 min and then were spun down at 16,000 *g* for 1 min at RT. The supernatant was reverse cross-linked by heating at 65°C overnight. Immunoprecipitated DNA was treated with 0.2 µg/ml RNaseA and 0.2 µg/ml proteinase K, both for 1 h. Phenol/chloroform/isoamyl alcohol extraction was performed followed by EtOH precipitation. Finally, the purified DNA was used as a template for qPCR analyses (see Table S1 for a list of primers). Each sample was loaded in triplicate, and the results were expressed as fold enrichment (specific ChIP/IgG enriched).

Online supplemental material {#s20}
----------------------------

Fig. S1 shows the expression of *Kdm4b* at early stages of otic development by ISH. Fig. S2 shows examples and quantitates the otic phenotypes observed in KDM4B-MO--treated embryos and rescued with a full-length or catalytically dead mutant of KDM4B. Fig. S3 shows that electroporation with a vector containing the full length of KDM4B, but not the catalytically dead mutant KDM4BΔ, is capable of erasing the H3K9me3 mark. Fig. S4 shows that the depletion of KDM4B affects proper nuclear orientation in the invaginating otic placode. Fig. S5 shows that coelectroporation of KDM4B-MO with pCIG-Dlx3 was sufficient to rescue cell death and otic vesicle size, whereas coelectroporation of KDM4B-MO with pCIG-Dlx5 is not enough to rescue the phenotype. Table S1 lists all of the primers used for qPCR. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201503071/DC1>.
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